ArticlePDF Available

Catalpol Increases Brain Angiogenesis and Up-Regulates VEGF and EPO in the Rat after Permanent Middle Cerebral Artery Occlusion


Abstract and Figures

To investigate the role and mechanism of catalpol in brain angiogenesis in a rat model of stroke, the effect of catalpol (5 mg/kg; i.p) or vehicle administered 24 hours after permanent middle cerebral artery occlusion (pMCAO) on behavior, angiogenesis, ultra-structural integrity of brain capillary endothelial cells, and expression of EPO and VEGF were assessed. Repeated treatments with Catalpol reduced neurological deficits and significantly improved angiogenesis, while significantly increasing brain levels of EPO and VEGF without worsening BBB edema. These results suggested that catalpol might contribute to infarcted-brain angiogenesis and ameliorate the edema of brain capillary endothelial cells (BCECs) by upregulating VEGF and EPO coordinately.
Content may be subject to copyright.
Int. J. Biol. Sci. 2010, 6
2010; 6(5):443-453
© Ivyspring International Publisher. All rights reserved
Research Paper
Catalpol Increases Brain Angiogenesis and Up-Regulates VEGF and EPO in
the Rat after Permanent Middle Cerebral Artery Occlusion
Hui-Feng Zhu
, Dong Wan
, Yong Luo
, Jia-Li Zhou
, Li Chen
, Xiao-Yu Xu
1. School of Pharmaceutical Sciences & School of Chinese Medicine, Southwest University, Chongqing 400715, China;
2. Department of Emergency Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016,
3. Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China;
4. Chongqing Medical And Pharmaceutical College;
5. Southwest University 2nd Hospital, Chongqing 400715, China
Corresponding author: Professor Xiao-Yu Xu, Laboratory of Molecular Pharmacology, School of Pharmaceutical Science
& School of Chinese Medicine, Southwest University, Chongqing 400715, China. Tel: +8 6 -23-6825-0761; Fax:
+86-23-6825-1225; E-mail:; xxy0618 @ s i n a .com
Received: 2010.05.24; Accepted: 2010.08.01; Publish ed: 2010.08.20
To investigate the role and mechanism of catalpol in brain angiogenesis in a rat model of
stroke , th e ef fect of catal pol (5 mg/kg; i.p) or veh icle administered 24 hours aft er p erma nent
middle cerebral artery occlusion (pMCAO) on behavior, angiogenesis, ultra-structural inte-
grity of brain capillary endothelial cells, and expression of EPO and VEGF were assessed.
Repeated treatments with Catalpol reduced neurological deficits and significantly improved
angiogenesis, while significantly increasing brain levels of EPO and VEGF without worsening
BBB edema. These results suggested that catalpol might contribute to infarcted-brain angi-
ogenesis and ameliorate the edema of brain capillary endothelial cells (BCECs) by upregulating
VEGF and EPO coordinately.
Key words: Catalpol, VEGF, EPO, Permanent occlusion of middle cerebral artery, Angiogenesis
1. Introduction
Stroke has been emerging as one of the most
c o m m o n c a u s e s o f m o r t a l i t y a n d m o r b i d i t y i n m o d e r n
society. A l t h o u g h m u c h p r o g r e s s h a s b e e n m a d e t o-
ward understanding the mechanistic basis of stroke,
the effectiveness of dru gs availa ble for stroke patients
is limited. Tissue plasminogen a ct i v a t o r ( T P A) , w h i c h
di ss olves bl ood c lots in the b rain, is pre se ntly th e on ly
approved treatment for stroke; however, it is effective
only in the first 3 h after the stroke and may lead to
cerebral hemorrhage [1]. Many drugs focus on the
isc he mic pe numb ra and c asc ad e of d ama ge , in cl uding
anti-N-meth y l -D-aspartate receptor (Aptiganel and
gavestinel), potassium channel agonists (MaxiPost),
and GABA modulators (Zendra). However, the uses
of these drugs for stroke have been abandoned be-
cause they are not effective and even harmful to
stroke patients, despite their apparent effectiveness in
animal models of brain ischemia [2]. Therefore, new
drugs a r e in demand an d need to be developed t o
treat stroke.
The neurovascular unit concept emphasizes not
only the neuron but also the brain vascular structure
[3-4]. Previous research on stroke has largely focused
on neuroprotection, but neglected the ischemic vas-
cular structure and the possible benefits of its func-
tional reconstruction [1,4,5]. Brain vascular structures
are coupled with brain neurons in structure and
function [6]. Angiogenesis is associated with neuro-
genesis [7]. Mounting evidence has shown that vas-
cular-remodeling occurs after st ro k e [ 8 -9]. It has been
Int. J. Biol. Sci. 2010, 6
shown that higher blood vessel counts correlate with
longer survival in stroke patients [ 10 ] . T h e
three-dimensional images of angiogenesis in the tis-
sue surrounding focal brain infarcts are demonstrated
by scanning electron microscopy with corrosion cast-
ing [11]. These studies suggest that targeting brain
vascular-remodeling for drug discovery is necessary
for stroke and even for ischemia disease.
Rehmannia Root is the main natural herbal
medicine that plays an important role in treat in g
stroke. Recently, catalpol, a main active component of
Rehmannia Root, was determined to pose extensive
ischemic neural protection, such as preventing the
loss of hippocampal CA1 neurons and reducing
working errors [12], modulating the expressions of
Bcl-2 and Bax [13], attenuating apoptosis in the
ischemic brain [13], and increasing hippocampal
neuroplasticity by up-regulating PKC and BDNF in
aged rats [14]. Catalpol improves Y-maze perfor-
mance and the survival of neurons in the CA1 sub-
field after transient global ischemia in gerbils [15-16] .
Our previous studies have demonstrated that catalpol
at doses of 10 and 5 mg/kg can improve neurobeha-
vioral outcome following permanent focal cerebral
ischemia in Sprague Dawley rats, and upregulate the
expression of growth-associated protein 43 (GAP-43)
[17]. These findings suggest that catalpol contributes
to neuroplasticity after stoke. However, whether cat-
alpol can modulate brain angiogenesis after focal
ischemia is unclear.
Erythropoietin (EPO) and Vascular en dothel ial
g r o w t h f a c t o r ( V E G F ) h a v e p l e i o t r o p i c e f f e c t s o n b r a i n
function, including neuroprotection, and promotion
of angiogenesis and neurogenesis [18]. Notably, EPO
enhances angiogenesis, without aggravating brain
edema, e ven u se d wi th VEG F [19].
In this study, we have investigated the effect of
catalpol on angiogenesis following permanent middle
cerebral artery occlusion (pMCAO) in rats. In order to
explore the cellular and molecular mechanism by
which catalpol may regulate the vascular plasticity of
the brain, we examined the expression of VEGF and
EPO by immunohistochemistry and western blotting.
2. Materials and Methods
2.1 Animals and diets
Healthy male Sprague-Dawley (SD) rats (220
280 g) were obtained from the Experimental Animal
Center, Chongqing University of Medicine, China.
Animals were housed under conditions of natural
illumination with food and water available ad libi-
tum. These experiments were performed in accor-
dance with Chinas guidelines for care and use of la-
boratory animals. An i m a l s w e r e d i v i d e d i n t o 3 g r o u p s
r a n d o m l y ( 1 ) t h e s h a m o p e r a t e d g r o u p ( n = 2 4 ) ; ( 2 ) t h e
vehicle group (n = 24); (3) the catalpol-treated group
(n = 24).
2.2 The pMCAO model
Strokes were induced by electrocoagulation of
the right middle cerebral artery as d es c ri b ed p r e-
viously with minor modifications [20]. B rie fly, rats
were anesthetized and placed in a stereotaxic instru-
ment (Shanghai Jiangwan) in the prone position. The
scalp was opened and brain was exposed, held up
lightly with a glass retractor, inferior cerebral vein
and olfactory bundle were seen perspicuously and the
right middle cerebral artery was along the brain sur-
face verticality striding over inferior cerebral vein and
olfactory bundle. The middle cerebral artery ventral
to the olfactory tract was electrocoagulated (power
35W), resulting in infarction of the right dorsolateral
cerebral cortex. Rats were prescreened to select those
in line with the criteria described as Bederson [21].
2.3 Drug administration
Catalpol was dissolved in physiological saline,
which was purchased from National Institute for the
Control of Pharmaceutical and Biological Products
(China) and its purity was more than 98%. Catalpol
(5mg/kg, ip) were administered 24h after stroke and
then daily for 7 days. Likewise, the sham-operation
group and the vehicle group received equal volumes
of physiological saline by ip injection. The dose of
catalpol was based on our previous study [17] and
Li’s study [15-16].
2.4 Bedersons Score
After operation, the neurological function of all
animals was evaluated daily with a 4-point scale as
previously described [21]: (0) no apparent deficit, (1)
contr ala teral f ore limb flexion , (2) lowe red r esista nce
to lateral push without circling, and (3) circling to
ipsilateral stroke if spontaneous activity.
2.5 B e a m -Walking test
Beam walking test [22-23] was used to evaluate
sensorimotor reflexes, motor strength and coordina-
tion. The testing apparatus was a 2.5 cm in diameter
and 80 cm in length wooden beam elevated 100 cm
a b o v e t h e f l o o r w i t h w o o d e n supports as described by
Stanley et al, and a 5cm thickness foam pillow placed
under the beam avoid getting wound in a fall.
Rats were allowed to walk to a platform located
at the end of the beam and their behaviors were rec-
orded based on the following six cri t e ri a : (0) the rat
traverses the beam without falling down; (1) the rat
traverses the beam but footslips less than 50%; (2) the
Int. J. Biol. Sci. 2010, 6
rat crosses the beam but footslips more than 50%; (3)
t h e r a t c r o s s e s t h e b e a m w i t h o u t t h e a i d o f t h e a f f e c t e d
hindlimb; (4) the rat cant traverses the beam but can
sit on the horizontal surface of the beam; (5) the rat
will fall down when placed on the beam. Each trial
consisted of five repetitions of this assay.
2.6 Examination of the healing Ischemic brain
cortex and the surface vessels
Stroke model rats in each group were sacrificed
15 days after the operation. After removing the sur-
face meninges, the surface vessels, distribution pat-
terns, and the healing state of ischemic cortex were
examined using a microscope attached to a digital
camera as described previously [24].
2.7 T is sue p re pa ra tio n
Fifteen days after operation/stroke induction,
the rats were deeply anesthetized with an overdose of
Chloral Hydrate (35 mg/mL, i.p), and transcardially
perfused with 0.9 % NaCl solution to rinse out the
blood, followed by 250 mL of 4% formalin (4°C) to fix
the brain tissue. After extraction from the skull, the
b ra i ns we re p os t -fixed in 4% formalin solution and
subsequently cut into 30 µm coronal sections on a
cryostat (Leica). For EPO analyses, imbedded brain
tissue was used. Ipsilateral ischemic cortex (0.1 g per
brain) in each group was also weighed for western
blotting a n aly ses .
2.8 Immunohistochemistry
Animal br a in tissues were transcardially per-
fuse d and fixed with 4% paraformaldehyde, cryopre-
served in 30% sucrose, and cut into three series of
consecutive sections (30 μm) at a Cryostat. Each set of
tissue sections was immunostained for PCNA, V W F
or VEGF. For EPO analyses, imbedded brain tissue
was used to cut as 5μm se ct ions. For immunohisto-
chemistry, tissue sections were incubated with rabbit
polyclonal antibody against EPO (1:200, santa cruz,
USA), VEGF(1:200, Wuhan Booster Biotech. Co.,
China). For double-fluo rescen ce labeli ng, cr oss se c-
tions were incubated with the vessel m a r k e r a n t i b o d y ,
rabbit polyclonal against VWF (1:200, Zhongshan
Biotech. Co., China), together with the mouse mo-
noclonal antibody against the proliferation marker
PCNA (1:200, Wuhan Booster Biotech. Co., China).
Immunohistochemistry for EPO was done with b i o-
tinylated goat anti-rabbit IgG (1:500; Vector Labora-
t or i es ) a nd p e ro xi da s e-conjugated avidin-biot in co m-
plex (ABC kit; Wuhan Booster Biotech. Co., China),
bound antibodies were visualized by addition of di-
aminobenzidine. V E G F s ec t i o ns then incubated with
Cy3-labeled goat anti-rabbit IgG (Wuhan Boster Bio-
tech. Co., China). PC NA a nd VWF then incubated
with Cy3-labeled goat anti-rabbit IgG (Wuhan Boster
Biotech. Co., China) a n d F I T C -labe led goat an -
ti-m o u s e I g G . After through washing, immunostained
ce lls w ere observed under a Nikon microscope and
were documented with a Nikon digital camera. Im-
munofluorescence staining for PCNA (green) and
VWF (red) or VEGF (red) was visualized and docu-
m e n t e d w i t h a c o n f o c a l m i c r o s c o p e (Le i c a) . According
to Acker [25] (Acker et al., 2001), the number of
double-stained vessels and the intensity of staining
were analyzed with Image Pro Plus Version 6.0.
software for cerebral microvessels at the boundary
zone of ischemia. Five fields of each slice were ran -
domly selected for blinded scoring and analyses. E a c h
experiment was performed three times.
2.9 Electron microscopy observation of brain
vascular endothelial cells
Rats in each group were anesthetized with 3.5%
chloral hydrate (35 mg/mL, i.p) and perfused for 2-3
min through the ascending aorta with 0.9% normal
saline, followed by ice-cold fixative (4% paraformal-
dehyde in 0.1 M PBS for 30 min). The brains were
removed for immunocytochemical electron micro-
scopic studies and fixed in 4% paraformaldehyde in
0 . 1 M P B S p H 7 . 4 f o r 3 4 h a t 4 ° C . T h e b r a i n w a s t h e n
rinsed in PBS for 30 min, treated with 1% OsO
for 30
min, dehydrated in sequential ethanol gradients, and
embedded in Epon 618. Ultrathin sections were
processed according to the postembedding proce-
dure. Briefly, ultramicrocut was made by Leica ul-
tramicrotome to collect 60nm-thick sections. The sec -
tions were mounted on formvar-c o at e d c o pp e r g r id s ,
incubated in uranyl acetate- acetate lead double elec -
t r o n s t a i n , a n d o b s e r v e d f o r b r a i n v a s c u l a r e n d o t h e l i a l
ce lls.
2.10 Western blotting
According to K.N. Na m [26] and Cao Hu ang
[27], brain cortex in peri-ischemic were lysed on ice in
lysi s b uf fer [50 m m T r i s -HC l (pH 8.2), 0.5 M saccha-
rose, 10 mMHEPES (pH 7.9), 1.5 mM MgCl2, 10 mM
KCl, 1 mM EDTA, 10% (v/v) glycerine, 1 mM DTT, 1
mM PMSF, 10μg/mL Aprotinin, and g/mL Leu-
peptin]. After centrifugation at 16,000 ×g for 10 mi-
nutes. Protein content in cleared lysate was deter-
mined by Bradford Assay. Lysate samples containing
40μg of p r o te i n were fractionated by SDS-1 0 % p o-
lyacrylamide gel electrophoresis and then electrob-
lotted onto P CV F membranes. The membranes were
probed with primary antibodies as EPO, VEGF (1:250,
1:300, Satcruze Co., USA) , an d β-a c t i n (1:200, Booster
Biotech. Co., Wuhan, China), then incubated with the
hors e ra d ish peroxidase-conjugated goat anti-mous e
Int. J. Biol. Sci. 2010, 6
or anti-rabbit IgG (1:2500; Booster Biotech. Co., Wu-
han, China), the PVDF membrane was put into DAB
fluid f o r coloration. Immunoreactivity was di gitall y
scanned b y ScanMaker E6 system a n d quantified us-
ing Q uanti ty one 4. 5.1 ( Bi o-Rad) software. β-ac t i n w a s
used as an internal control for all Western blotting.
2.11 Image and data analysis
After capturing images with a digital camera,
quantification of the results from immunohistoche-
mistry, immunofluorescence, western blotting was
performed with Image Pro Plus Version 6.0. software.
EPO or VEGF-positive cells were counted at five dif-
ferent fields in the inner border of the peri-ischemic
cortex in five sections per rat, the to ta l nu mb er o f EP O
o r V E G F -positive cells per image (cells/cm
, o b j e c t i v e
× 20) was calculated by an observer blind to the ex-
perimental treatment. In each section, five pe -
ri-ischemia cortical areas outside labeled neurons
were chosen randomly to obtain an average value for
the subtraction of background by an observer blind to
the experimental treatment.
2.12 Statistical analyses
Data were expressed as mean ± S .E .M. Al l d ata
were analyzed by one-way analysis of variance
(ANOVA) using SPSS 11.0 software. A value of p <
0.05 was co nsider ed sta tistic ally s ignifi cant.
3. Results
3.1 Catalpol improve sensorimotor performance
in stroke rat s
Post-stroke administration of catapol reduced
Bederson's score in rats, indicating improved motor
function re lative to v ehicle c ontrol , catap ol sign ifi-
cantly reduced Bederson's scores in rats at 7 and 15
da ys after s trok e (Fig. 1 A).
The Beam walking test w as us ed to m e as ur e
sensorimotor function. During the course of treat -
ment, beam walking scores were reduced; by day 15
following stroke, score reductions in catapol-treated
versus vehicle-treated animals reached statistical sig-
nificance (P< 0.05) ( Fi g. 1B ).
Figure 1. Effects of intraperitoneal injection with catalpol on sensorimotor performance in post-surgical
rats at days 1, 4, 7 and 15. (A) Post-stroke treatment with catalpol reduced Bederson’s score in stroke rats and (B)
decreased beam working score in stroke rats. T h e d a t a a r e p r e s e n t e d a s m e a n ± SE. * p<0.05 compared with vehicle group,
p<0.01 compared with sham operation g ro up.
Int. J. Biol. Sci. 2010, 6
3.2 Effect of catalpol on the vascular pattern of
the cerebral cortex surface
The effect of catalpol on the vascular pattern of
the rat cerebral cortex surface was examined follow-
ing pMCAO. In vehicle-treat ed a nimals , li quefa c t i v e
necrosis of the brain was observed 15 days after
p MC AO . B ra in s fr o m vehicle-treated animals exhi-
bited a few deranged microvessels (F ig u re 2A ). B y
contrast, the focus of cerebral ischemia was near
normal in catalpol-treated animals; the brains of thes e
animals exhibited more branched vessels crossing and
gathering radially to the surface of cerebral ischemia.
All these vessels arborized to form a continuous net-
work of small blood vesse l s (F ig ur e 2B ).
Figure 2. T h e vascular pattern in cerebral cortical surface in rats 15 days after pMCAO. (A) In the ve-
hicle-tr e ated group, the pale brain surface had few vessel branch points, infarct areas were characterized by liquefactive
necrosis, cortical surface vessels were scarce and rearranged, several discontinued vascular structures were observed, and
the radial patterns were lost . (B) In the catalpol-treated group, brain surface vessel branch points increased obviously,
vascular structures continued, focus on the infarct area was present, and the vessel radial patterns and brain tissue infarct
area were close to normal. Arrow points to vascular structures around the ischemia area.
3.3 Catalpol enhanced brain angiogenesis in the
peri-infarcted area of the cortex
The effect of catalpol on angiogenesis was then
examined by immunostaining of brain sections for
von Willebrand Factor (vWF), a marker of endothelial
cells, and for proliferating cell nuclear antigen
(PCNA), a marker of cell proliferation. V WF a n d
PCNA co-localization points in the sham o p e ra t i o n
group were scarcly observed (F ig 3A).C o m p a r e d w i t h
the v ehic le-treated g r o u p ( 34 ± 3.25) (Fi g 3B) , t he
number of VWF and PCNA co-localization points in
the catalpol-treated group (Fig 3C an d D ) in c re a se d
significantly (p < 0.05). The number of vWF and
PCNA co-localization points in the catalpol-treated
gr ou p (F ig 3C and D) was 233.67 ± 89.51, nearly 6
times that in the vehicle group (p < 0.01) (Fig 3B an d
D). These results also agreed with results o b ta in e d
from integral optical density (IOD) analyses in the
vWF-P C N A c o -localization area (Fig 3E). These data
demonstrate that catalpol plays an important role in
cerebral ischemia angiogenesis.
3.4 Effects of catalpol on brain capillary endo-
thelial cells (BCECs)
The influence of catapol treatment on BCEC mi-
crostructure following pMCAO were examined by
transmission electron microscopy. Compared to ve-
hi cle co tntrol (F ig 4A), catalpol significantly reduced
BCEC edema (Fig 4B). The number of chondriosomes
in the catalpol-treated group was hi ghe r than that in
the vehicle group and close to normal levels.
Int. J. Biol. Sci. 2010, 6
Figure 3. Angiogenesis surrounding ischemic cortical area as demonstrated by immunocytochemistry and
laser scanning confocal microscopy. The effects of Catalpol on angiogenesis were indicated by double-stai ning for
VWF, a marker of endothelial cells and for proliferating cell nuclear antigen (PCNA), a marker of cell proliferation.
Co-labeling of PCNA (green) and VWF (red) demonstrates angiogenesis, i.e., endothelial proliferation in the capillaries, in
the peri-i n f a r c t e d a r e a a t 1 5 d a y s a f t e r p M C A O . C o -localization of P C N A a n d V W F i s y e l l o w . ( A ) S h a m o p e r a t i o n g r o u p , ( B )
Vehicle-treated group, (C) Catalpol-t r e a t e d g r o u p . B a r s = 1 5 0 μm i n A , B , a n d C . T h i s a n a l y s i s d e m o n s t r a t e d that few vessels
were double-s t a i n e d b y V W F a n d P C N A i n s h a m -operated rats (A), but significa n t r e m o d e l i n g o f t h e m i c r o v e s s e l n e t w o r k
o c c u r r e d i n t h e i n f a r c t e d h e m i s p h e r e a n d t h e n u m b e r o f v e s s e l s w i t h s m a l l d i a m e t e r a n d s h o r t s e g m e n t i n c r e a s e d a t 1 5 d a y s
after the stroke. More vessels were double-s t a i n e d f o r V W F a n d P C N A i n c a t a l p o l -treated group (C). Statistical analyses are
s h o w n i n t h e g r a p h o f t h e n u m b e r o f v e s s e l s c o - l a b e l e d f o r P C N A a n d V W F ( D ) . T h e r e s u l t s a b o v e a g r e e d w i t h t h e r e s u l t s
of IOD analyses in the co-localization area (E). (
P < 0.01).
Int. J. Biol. Sci. 2010, 6
Figure 4 Ultrastructural observations of brain capillary endothelial cells (BCECs). In the vehicle-t re at ed gr ou p
( A ) , B C E C e d e m a , c h r o m a t i n r a r e f a c t i o n ( s h o r t a r r o w ) , a n d c h o n d r i o s o m e s w e l l i n g ( l o n g a r r o w ) w e r e o b s e r v e d . ( B ) I n t h e
catalpol group, BCECs, pykno-chromatin (short arrow), and chondriosome number and shape (long arrow) were close to
normal or near normal. Bars = 1μm.
3.5 Catalpol upregulated EPO and VEGF ex-
pression in rat brain following pMCAO
To monitor the influence of catapol on EPO and
VEGF expression, we performed immunohistochem-
ical analyses of brain sections derived from rats fol-
lowing pMCAO. EPO and VEGF- positive cells w er e
detected in the cell membrane and cyt o p l a sm . Fe w
EPO positive cells were observed in brain sections
derived from sham-treated animals ( Fi g 5A). Com-
pared to vehicle-treated animals (Fig 5B), brain sec-
tions derived from catapol-treated animals exhibited
significantly increased EPO expression (Fig 5C). Sta-
tistical analyses revealed 7.2 ± 1.40 positive cell/cm
vs 15.3 ± 2 positive cell/cm
in vehicle-treated versus
catapol-treated animals (p < 0.05). Similar results were
obtained by western blot analyses (Fi g 5G and I); A s
for V EG F, immunofluorescence analyses demon-
strated that catalpol at the dose of 5mg/ kg signifi-
cantly upregulated VEGF expression compared with
the vehicle group; the number of positive cell/cm
vehicle-treated versus catapol-treated animals was 8±
1.6 vs 17 ± 2.5; (p < 0 .01) (F ig . 5E , F, H) . Once again,
similar results were obtained by western blot analyses
(Fig 5G a n d I ) . Statistical analyses were shown in Fig
4. Discussion
There are three principal findings emerged from
the present study. Firstly, catalpol treatment im -
proved neurofunction after stroke, as evidenced by
enhanced scores in the beam walking test designed to
evaluate sensorimotor reflexes, motor strength and
coordination. Secondl y, o ur resu lts show that catapol
enhances brain angiogenesis following stroke without
wo rs en i ng stroke brain ed e ma . Fina lly, we demon-
strate that t h e ameliorative effects of catalpol on
stroke brain are mediated by enhanced expression of
EPO and VEGF. Our findings thus provide new in -
sights into the likely regulatory mechanisms of cata-
Ischemic stroke is a serious dis e as e caused by a
thrombus (blood clot), w h i c h c a n r e s u lt i n p e r m an e n t
neurological damage, complications, and even d ea th
[26].Th e standard m e th o d of treatment is t o dissolve
the clot a n d r e s t o r e blood flow in the b l o c k e d vessel.
The drug TP A is approved for this use; however, TPA
is used onl y 3-6 hours after stroke, a n d the more ra-
pidly blood flow is restored to the brain, the fewer
brain cells die [27]. Recent research has suggested that
an alternative approach to restore blood flow is to
promote angiogenesis in regions surrounding the
ischemic brain.
As one of the most potentangiogenic factors,
VEGF is up-regulated by focal cerebral ischemia not
only in animal models but also in human patients
[10-11] as an angiogenic, neurotrophic, and neuro-
protective factor [28-30]. VEGF also plays a vital role
d u r i ng n e u r a l [29,31] and vascular remodeling [32 -33]
after stroke. Our results showed that ischemia in -
duced VEGF expression, which was not enough for
vascular remodeling, but catalpol treatment increased
VEGF expression together with increased microvessel
f or m at i on , he al ed t h e ischemic brain, and improved
neurobehavioral score. These data suggested that cat-
alpol stimulated brain angiogenesis after stroke by
increasing the secretion of endogenous VEGF.
Int. J. Biol. Sci. 2010, 6
Figure 5 Catalpol upregulated EPO and VEGF expression in pMCAO rat brains. Immunohistochemistry results
showing neurons with EPO (A, B, C, 200×) and VEGF (D, E, F, 20) in the peri-infarcted area of a pMCAO rat, a
sham-operated rat (A & D), a vehicle-treated rat (B & E), and a catalpol-treated rat (C & F). EPO and VEGF expression
detected by western blot showed in (G). The internal control was β-actin. Vs vehicle group
p < 0.05 . The experiments
repeated three times and 6 rats used in eac h group. Statistical bars shown as H and I respectively.
Int. J. Biol. Sci. 2010, 6
Moreover, VEGF, known as vascular permeabil-
ity factor, is associated with angiogenesis, vascular
permeability and neuroprotection. VEGF enhances
angiogenesis, but worsens rather than improves ce -
rebral haemodynamics after stroke [34-35]. Lo w-dose
VEGF aggravates hemorrhagic transformation [36].
Inhibition of endogenous VEGF by topical application
of anti-VEGF antibody in the ischemic cortex de-
creased the blood-brain barrier (BBB) disruption [37].
VEGF is in part responsible for the BBB disruption
during the early stage of focal cerebral ischemia [37] .
These adverse effects suggested that caution should
be heeded when considering the use of only VEGF for
stroke patients [38].
EPO is a pleiotropic factor [39] . EP O and EPO
receptor (EP O -R) are expressed in neurons, astrocytes,
and endothelial cells after focal permanent ischemia
in mice. EPO is a neuroprotective factor [40-41], which
improves functional recovery and reduces neuronal
apoptosis [42] and inflammation [43]. EPO has a mi-
togenic and positive chemotactic effect on endothelial
cells and endothelial progenitor cells [44-45]. It sti-
mulates angiogenesis in vitro and i n v i v o [18,40].
Therefore, the EPO/EP O -R system is implicated in
the process of neuroprotection [4 6] and restructuring
(such as angiogenesis) after ischemia [18,46]. In this
study, catalpol increased EPO expression in neurons
and endothelial-like cells surrounding the vessels.
Therefore, catalpol may improve neurofunction and
neural and vascular remodeling after stroke by acti-
vating EPO .
In this study, we observed that catalpol in-
creased VEGF expression but did not increase vascu-
lar permeability (Fig 3b), which may be related to the
simultaneous increase of EPO expression in the brain.
EPO reduces the side effects of VEGF, which protects
the BBB against VEGF-induced permeability in vitro
[19]. EPO and VEGF promote neural outgrowth
(Bocker-Meffert et al., 2002) and exhibit equal angi-
ogenic potential [18]. Furthermore VEGF modulates
erythropoiesis through regulation of adult hepatic
erythropoietin synthesis [ 47], a n d EPO -R promotes
V EG F e xp re ssion and angiogenesis in peripheral
ischemia in mice [48]. Therefore, the advantageous
reciprocal interactions between EPO and VEGF on
angiogenesis, which can be induced by catapol may
be an effective way to treat stroke patients. Brain in -
j u r y h e l p s E PO to cross the BBB [49-50], w h i c h m a y
then produce a synergistic effect with VEGF. Catalpol
is the effective component of Rehmannia glutinosa,
which can increase blood level o f EPO (data not
shown). Moreover, catapol can cross the BBB, as de-
tected by HPLC even in normal rats [51].
In conclusion, our data suggested that catalpol
modul ated angiogenesis through increased EPO and
VEGF after stroke, which may be the mechanism by
which catalpol reduced ischemic neuronal damage
and enhanced functional recovery. Taken to ge t he r ,
these data suggested that catalpol may improve col-
lateral circulation and pr o vi d e impact on stroke pa-
tients through new blood vessel formation. Future
research may elucidate the specific signaling path-
ways through which catalpol increases angioge n es i s.
This work was supported by grants from the
Fundamental Research Funds for the Central Univer-
sities (No.XDJK2009C081) and Southwest University
Dr. Foundation (No.104290-20710906) and N SF C
General Projects (No.81073084).
Conflict of Interests
The authors have declared that no conflict of in-
terest exists.
1. Beenken S.W., Bl and K.I. Biomark ers for br east ca ncer. Minerva
Chir. 2002;57:437-448.
2. Albers G.W., Goldstein L.B., Hall D., et al. Aptiganel hydroch-
loride in acute ischemic stroke: a randomized controlled trial.
Jama. 2001; 286:2673-2682.
3. Girouard H., Iadecola C. Neurovascular coupling in the normal
brain and in hypertension, stroke, and Alzheimer disease. J
Appl Physiol. 2006;100:328-335.
4. Iadecola C. Neurovascular regulation in the n ormal b rain a nd
in Alzheimer's disease. Nat Rev Neurosci. 2004; 5:3 47-360.
5. Krupinski J., Kaluza J., Kumar P., et al. Some remarks on the
growth-rate and angiogenesis of microvessels in ischemic
stroke. Morphometric and immunocytochemical studies. Pato l
Pol.1993; 44:203-209.
6. Craven R. Go with the flow. Nature review 20 02;3:585.
7. Morris DC, Yeich T, Khalighi MM, et al. Microvascular struc-
ture after embolic focal cerebral ischemia in the rat. Brain
Res.2003, 972:31-37.
8. Hawkins B.T., Davis T.P. The blood-brain barrier/ neurovas-
cular unit in health and disease. Pharmacol Rev 2005;
9. Lo E.H., Broderick J.P., Moskowitz M.A.. tPA and proteolysis in
the neurovascular unit. Stroke. 2004;35:354-356.
10. Krupinski J., Kaluza J., Kumar P., et al. Role of angio gene sis in
patients with cerebral ischemic stroke.
11. Krupinski J, Stroemer P, Slevin M, et al. Three-dimensional
str uc -ture and survival of newly formed blood vessels after
focal cerebral ischemia. Neuroreport.2003;14:1171-1176.
12. Li D.Q., Li Y., Liu Y., et al. catalpol prevents the loss of CA1
hippocampal neurons and reduces working errors in gerbils
after ischemia-reperfusion injury. Toxicon 2005;46:845-851.
13. Li D.Q., Bao Y.M., Li Y., et al. catalpol modulates the expres-
sions of Bcl-2 and Bax and attenuates apoptosis in gerbils after
ischemic injury. Brain Res. 2006; 1115:179-185.
Int. J. Biol. Sci. 2010, 6
14. Liu J H.Q., Zou W, et al. catalpol increases hippocampal neu-
rop-lasticity and up-regulates PKC and BDNF in the aged rats.
Brain Res.2006; 23:68-79.
15. Li D.Q., Bao Y.M., Zhao J.J., et al. Neuroprotective properties o f
catalpol in transient global cerebral ischemia in gerbils:
dos e-response, therapeutic time-win dow an d long-t erm ef-
fi-cacy. Brain Res 2004; 1029:179-185.
16. Li D.Q., Duan Y.L., Bao Y.M., et al. Neuroprotection of catalpol
in transient global ischemia in gerbils. Neurosci Res
17. H.F Zhu, Dong Wan, Yong Luo, et al. catalpol up-regulated
GAP-43 protein expression and improved behavior outcome in
focal cerebral ischemia rats. Chinese Pharmacological Bulletin.
18. Jaquet K., Krause K., Tawakol-Khodai M., et al. Erythropoietin
and VEGF exhibit equal angiogenic potential. Microvasc Res.
19. Martinez-Estrada O.M., Rodrig uez-Millan E., Gonzalez-D e
V i c e n t e E . , e t a l . Erythropoietin protects the in vitro blood-bra in
barrier against VEGF-induced permeability. Eur J Neurosci.
20. C h e n P , G o l d b e r g D E , K o l b B L . M . , e t a l . I n o s i n e i n d u c e s a x o n a l
rewiring and improves behavioral outcome after stroke. Proc
Natl Acad Sci U S A. 2002; 99:9031-9036.
21. Bederson L.H. Pitts, and Daves RL. Rat middle cerebral artery
occlusion: evaluation of the model and development of a neu-
rologic examination. Stroke.1986;17:472-476.
22. G. Stanley K. Harvey V. Slivova, et al, Ganoderma lucidum
sup -pr esse s angi ogen esis through th e i nhib ition of secr etio n of
VEGF and TGF-beta1 from prostate cancer cells. Biochem Bio-
phys Res Commun. 2005;330:46-52 .
23. Takata K, Yamauchi H, Tatsuno H, et al. Is the ipsilateral cortex
surrou ndin g the l esion or t he no n-injured contralateral cortex
important for motor recovery in rats with photochemically in-
duced cortical lesions? Eur Neurol 2006;56:106-112.
24. Zhang ZG Z.L., Tsang W, Soltanian-Zadeh H, et al. Correlation
of V EGF a nd an giop oietin ex pressi on wi th di srup tion of
blood-brain barrier and angiogenesis after focal cerebral
ischemia. J Cereb Blood Flow Metab. 2002, 22:379-392.
25. Acker T., Beck H., Plate K.H. Cell type specific expression of
vascular endothelial growth factor and angiopoietin-1 and -2
sug gest s an important role of astrocytes in cerebellar vas-
cu-larization. Mech Dev. 2001;108:45-57.
26. K.N. Nam et al. Genipin inhibits the inflammatory response of
rat brain microglial cells. International Immunopharmacolo-
gy.2010, 10:493499.
27. Cao Huang, Pedro Yuxing Xia, Hon gxia Zho u. Su stai ned E x-
pres-sion of TDP-43 and FUS in Motor Neurons in Rodent's
Life-time. Int J Biol Sci 2010,6:396 -406.
28. Sims NR, Muyderman H. Mitochondria, oxidative metabolism
and cell death in stroke. Biochimica et Biophysica Acta.
2009,1802 (1): 8091.
29. The European Cooperative Acute Stroke Study (ECASS).
Throm-bolysis with Alteplase 3 to 4.5 Hours a fter Acu te
Ischemic Stroke. New England Journal of Medicine 2008, 359
(13): 13171329.
30. Che n Y.H. , W u H.L. , C hen C.K. , e t al . A ngio statin ant agon izes
the action of VEGF-A in human endothelial cells via two dis-
tinct pathways. Biochem Biophys Res Commun.
31. Jin K., Mao X.O., Greenberg D.A. Vascular endothelial growth
facto r s timu late s n euri te ou tgrowth from cere bral co rtic al neu-
rons via Rho kinase signaling. J Neurobio. 2006; 66: 236-242.
32. Yasuhara T., Shingo T., Kobayashi K., et al. Neuroprotective
effects of vascular endothelial growth factor (VEGF) upon do-
pa mine rgic neu rons in a ra t mo del o f Pa rkin son's dis ease . E ur J
Neurosci.2004, 19:1494-1504.
33. Wang Y., Jin K., Mao X.O., et al. VEGF-overexpressing trans-
genic mice s how en hanced po st-is chem ic neu rogenesis and
neu-romigration. J Neurosci Res.2007, 85:740-747.
34. Kanno S., Oda N., Abe M., et al. Roles of two VEGF receptors,
Flt-1 and KDR, in the signal transduction of VEGF effects in
human vascular endothelial cells. Oncogene. 2000;19:2138-2146.
35. Louissaint AJr., Rao S., Leventhal C., et al. Coordinated
inte-ra ctio n of neu roge nesi s and a ngio gene sis i n the a dult
songbird brain. Neuron 2002,34:945-960.
36. Wang Y., Kilic E., Kilic U., et al. VEGF overexpression induces
post-ischaemic neuroprotection, but facilitates haemodynamic
steal phenomena. Brain. 2005, 28:52-63.
37. Zhang Z.G., Zhang L., Jiang Q., et al. VEGF enhances angi-
oge-nesis and promotes blood-br ain barrier leakage in the
ischemic brain. J Clin Invest. 2000,106:829-838.
38. Abumiya T., Yokota C., Kuge Y., et al. Aggravation of hemorr-
hagic transformation by early intraarterial infusion of low-dos e
vascular endothelial growth factor after transient focal cer eb ra l
ischemia in rats. Brain Res. 2005; 1049:95-103.
39. Chi O.Z., Hunter C., Liu X., et al. Effects of anti-VEGF antibody
on blood-brain barrier disruption in focal cerebral ischemia.
Exp Neurol. 2007;204:283-287.
40. Manoonkitiwongsa PS S.R., McCreery DB, Whitter EF, et al.
Neu-roprotection of ischemic brain by vascular endothelial
g r o w t h f a c t o r i s c r i t i c a l l y d e p e n d e n t o n p r o p e r d o s a g e a n d m a y
be compromised by angiogenesis. J Cereb Blood Flow Me-
tab.2004, 24:693-702.
41. Kitadai Y., Sasaki A., Ito M., et al. Helicobacter pylori infection
influences expression of genes related to angiogenesis and in-
vasion in human gastric carcinoma cells. Biochem Biophys Res
Commun. 2003; 311: 809-814.
42. Marti H.H. Erythropoietin and the hypoxic brain. J Exp Bi-
ol.2004, 207:3233-3242.
43. Sola A., Rogido M., Lee B.H., et al. Erythropoi etin after Focal
Cere bral Ischemia A ctiv ates t he Ja nus Ki nase Signal
Trans-ducer and Activator of Transcription Signaling Pathway
and Improves Brain Injury in Postnatal Day 7 Rats. Pediatr
Res.2005, 57: 481-487.
44. Kretz A., Happold C.J., Marticke J.K.,et al. Erythropoietin
promotes regeneration of adult CNS neurons via Jak2/Stat3
and PI3K/AKT pathway activation. Mol Cell Neurosci. 2005;
45. Zhang J., Li Y., Cui Y., et al. Erythropoietin treatment improves
neurological functional recovery in EAE mice. Brain Res.
46. A n a g n o s t o u A . , L e e E . S . , K e s s i m i a n N . , e t a l . E r y t h r o p o i e t i n h a s
a Mitogenic and Positive Chemotactic Effect on Endothelial
Cells. PNAS. 1990; 87: 5978-5982.
47. Burbelo P.D., Ching K.H., Mattson T.L., et al. Rapid antibody
quantification and generation of whole proteome antibody re-
sponse profiles using LIPS (luciferase immunoprecipitation
systems). Biochem Bi ophys Res Commun. 2007 ; 352:889-895.
48. Bernaudin M., Marti H.H., Roussel S., et al. A potential role for
erythropoietin in focal permanent cerebral ischemia in mice. J
Cereb Blood Flow Metab. 1999; 19:643-651.
49. Tam B.Y., Wei K., Rudge J.S., et al. VEGF modulates erythro-
poiesis through regulation of adult hepatic erythropoietin
syn thes is. Nat Med. 2006,12:793-800.
50. Nakano M., Satoh K., Fukumoto Y., et al. Important role of
eryt-hropoietin receptor to promote VEGF expression and an-
gi-ogenesis in peripheral ischemia in mice. Circ Res.
51. Brines M.L., Ghez zi P., Keenan S.,et al. Erythropoietin crosses
the blood-brain barrier to protect against experimental brain
in-jury. Proc Natl Aca d Sci U S A. 2000; 97:10526-10531.
Int. J. Biol. Sci. 2010, 6
52. Statler P.A., McPherson R.J., Bauer L.A., et al. Pharmacokinetics
of High-Dose Recombinant Erythropoietin in Plasma and Brain
of Neonatal Rats. Pediatr Res.2007,61:671-67 5
53. He Yao, Zhu Huifeng, Li Wanyu, et al. HPLC determination of
catapol in cerebrospinal fluid of rat. China Journal of Chinese
Materia Medica. 2009;34(13):1717-171
... Catalpol has been assessed widely for its biological properties in vitro and in vivo [18]. Although catalpol is more toxic to generalist herbivores than aucubin [3,43,170,173], the research on its properties has shown various pharmacological effects, including sedative, anti-inflammatory, analgesic, anti-tumor, liver protective, anti-microbial (Table 7), purgative, anti-apoptosis actions, and anti-catarrhal for the upper and lower respiratory tract [174][175][176]. In addition to the listed activities, catalpol has been confirmed as a significant neuroprotective agent against experimental Alzheimer and Parkinson diseases. ...
Full-text available
Background: Plantago species contain aucubin and catalpol iridoid glycosides used in traditional medicine for many purposes. Objectives: To accelerate the utilization of aucubin and catalpol in Plantago species, research should be focused on introducing advanced purification and detection methods. In this regard, the therapeutic activities of aucubin and catalpol compounds are mentioned to confirm their effectiveness in medicinal uses. Methods: An extensive literature search was conducted using the keywords “Aucubin and Catalpol + Plantago” in the public domains of Google scholar. Results: The iridoid patterns exhibited a significant correlation with morphological and other chemical specifications of the representatives of the genus Plantago. Commonly, iridoid glycosides are detected with gas chromatography, liquid chromatography, thin-layer chromatography, high-performance liquid chromatography (HPLC), high-performance thin-layer chromatography (HPTLC), and capillary electrophoresis techniques. The most common methods are HPLC and HPTLC. Aucubin and catalpol are active compounds possessing biological activities, including anti-cancer, anti-aging, anti-inflammatory, anti-oxidant, hepatoprotective, osteoprotective, and neuroprotective properties. Conclusion: This review article comprehensively summarizes cytotoxic activities and detection methods of aucubin and catalpol in Plantago species. The results suggest that Plantago species and their metabolites may benefit human health beyond their traditional uses.
... Pharmacologically, unprocessed and processed R. glutinosa have shown to possess several biological activities, such as inhibition of tumoral processes (antitumor activity) through their action on the enzyme topoisomerase I [2] and are toxic to the lung cancer cell lines (cytotoxicity) [3]. Specifcally, catalpol shows extensive protection for neuronal ischemia [4], elevates brain angiogenesis [5], and possesses hypoglycemic and diuretic abilities [1]. On the other hand, harpagide shows leishmanicidal activity [6] and is capable of downregulating the production of enzymes, such as lipopolysaccharide-induced nitric oxide synthase and cyclooxygenase-2 (COX-2) through suppression of nuclear factor κB [7]. ...
Full-text available
Rehmannia glutinosa (Gaertn.) DC., belonging to the family Scrophulariaceae, has been known since immemorial times as a prominent oriental drug in East Asia that can treat various ailments, such as kidney disorders, anemia, and diabetes. In order to be applied for medical purposes, R. glutinosa is commonly processed using steam to increase its efficacy and biological activity. The increasing demand for R. glutinosa in the traditional medicine industry encouraged many researchers to develop a fast, efficient, and high-quality production system using biotechnological approaches. This study aimed to compare the chemical and biological activities of in vitro regenerated R. glutinosa (PKR) and commercial R. glutinosa (PCR) samples subjected to steam processing. We assessed the effects of steam processing and the differences in R. glutinosa material on 5-Hydroxymethyl-2-furaldehyde (5-HMF) content, total flavonoid and phenolic content, antioxidant activity, nitric oxide (NO) levels, and anti-inflammatory activity. PKR samples showed a significantly higher content of 5-HMF (0.15%) as compared to PCR samples (0.05%). Compared to unprocessed R. glutinosa (UPR) and PCR samples, PKR again showed the highest total phenolic and flavonoid content of 41.578 mg GAE/g and 17.208 mg RUE/g, respectively. Meanwhile, both processed R. glutinosa samples (PKR and PCR) showed a significantly higher DPPH antioxidant activity ((67.095 + 1.005)% and (61.579 + 0.907)%, respectively) than unprocessed R. glutinosa ((31.452 + 1.371)%). In addition, both PKR and PCR samples showed good anti-inflammatory activity by showing similar effects such as the inhibition of NO production and the suppression of inducible nitric oxide synthase (iNOS). Based on these results, PKR fulfilled the Chinese pharmacopeia standards, in terms of the amount of the marker compounds and showed a high level of bioactivity. Therefore, these findings are expected to be useful in verifying the efficacy of herbal medicines and the availability of suitable materials for medicinal use.
... Subsequently, a marker of endothelial cells (CD31) and a marker of cell proliferation (proliferating cell nuclear antigen, PCNA) were used to further estimate the effects of Cu-EGCG on angiogenesis [46,47]. There was a report that the injection of copper ions could upregulate the expression of CD31 in ischaemic tissues [48]. ...
Lesions of patients with peripheral artery disease (PAD) are in a harmful microenvironment, which features increased oxidative stress and inflammatory infiltration. Hence, it is essential to improve the microenvironment along with angiogenesis. In this study, metal-polyphenol capsules (Cu-EGCG), which combines the therapeutic anti-inflammatory and antioxidant activities of EGCG and the angiogenic activity of copper ions, were synthesized through coordination between EGCG and copper ions. The sustained release of the copper ions from Cu-EGCG was demonstrated in vitro, and biocompatible Cu-EGCG can scavenge intracellular ROS, reduce cell death in the presence of cytotoxic levels of ROS, and decrease the expression of pro-inflammatory cytokines (TNF-α, IL-6). Moreover, Cu-EGCG induced the secretion of vascular endothelial growth factor (VEGF) in a hindlimb ischaemia model of PAD. More importantly, the upregulated expression of platelet endothelial cell adhesion molecule-1 (CD31) and proliferating cell nuclear antigen (PCNA) in ischaemic tissues indicated the remarkable effect of Cu-EGCG on angiogenesis. In addition, Cu-EGCG showed significant blood recovery in ischaemic hindlimbs. Taking these results together, biocompatible Cu-EGCG with therapeutic functions holds great potential applications for PAD therapy.
... Our study detected that CAT treatment increased the levels of MMP9, Cadherin 5, and VEGF in flaps, indicating CAT has positive effects on angiogenesis. Consistent with the previous study that reported CAT exerted a therapeutic effect in infarcted-brain through promoting angiogenesis [29], our results demonstrated that CAT could enhance the survival of flap via improving blood supply. ...
Full-text available
Random-pattern skin flap necrosis limits its application in the clinic. It is still a challenge for plastic surgeons. Catalpol is an effective ingredient extracted from Rehmannia glutinosa, which is reported to promote angiogenesis and protect against ischemic cerebral disease. The aim of our experiment is to assess whether catalpol can facilitate random flap survival and the underlying mechanisms. Male “McFarlane flap” rat models were employed to explore the protective effects of catalpol. The range of necrosis in the flap was calculated 7 days after the models were established. The flap specimens were harvested for further experiments, including angiogenesis, apoptosis, oxidative stress, and autophagy evaluation. Catalpol-treated group promoted the average survival area of the flap than that in the control group. Based on immunohistochemical staining, Western blotting, and ROS detection, we found that catalpol significantly reduces oxidative stress and apoptosis and increases angiogenesis. Hematoxylin and eosin (H&E) staining and laser Doppler images further clarified the enhancement of angiogenesis after catalpol treatment. The impact of catalpol in flap was switched by using 3-methyladenine (3MA), proving the important role of autophagy in curative effect of catalpol on skin flaps. Importantly, the ability of catalpol to regulate autophagy is mediated by the activation of sirtuin 1 (SIRT1) based on its high affinity for SIRT1. Our findings revealed that catalpol improved the viability of random skin flaps by activating SIRT1-mediated autophagy pathway.
... Catalpol can promote angiogenesis in the ischemic brain area, protect cerebral neurovascular units, and promote the recovery of neurological function in stroke rats. 22,25 Central Nervous System (CNS) diseases include stroke, brain tumor, CNS infection, migraine, etc. The lesion is located in the brain, but due to the existence of blood-brain barrier (BBB), many drugs cannot be administered in sufficient effective amount to the brain. ...
Full-text available
Purpose: Catalpol is the main active component of Rehmannia glutinosa, which has a variety of pharmacological activities, including anti-inflammatory and anti-oxidative effects. This study investigates the feasibility of catalpol intranasal administration and its protective effect on acute cerebral ischemia in rats via anti-oxidative and anti-apoptotic mechanisms. Patients and methods: This study investigates the method of catalpol intranasal administration to evaluate the nasal mucosal toxicity, brain targeting and pharmacokinetics of catalpol. The protective effect of catalpol of intranasal administration on stroke-induced brain injury in rats and its mechanisms on oxidative stress pathway Nrf2/HO-1 and apoptosis were also investigated using middle cerebral artery occlusion (MCAO). Results: The results showed that catalpol intranasal administration was safe and feasible with no hemolysis, no bad effect on the maxillary ciliary movement of bullfrog. After intranasal administration, the brain targeting index (DTI) of catalpol was greater than 1, which indicated that catalpol had good brain targeting after intranasal administration. The bioavailability of catalpol administered intranasally was higher than that of in plasma. In MACO model, catalpol intranasal administration could significantly reduce cerebral infarction volume, neurological dysfunction and brain edema. In addition, catalpol intranasal administration can also reduce the brain cell's occurrence of apoptosis, promote the expression of Bcl-2 protein and inhibit the expression of Bax protein, reduce oxidative stress damage via up-regulating expression of Nrf2 and HO-1, increasing the activities of SOD and decreasing the activities of MDA. Conclusion: Collectively, catalpol intranasal administration has good safety, stability and brain targeting. It can effectively protect the brain injury of the rat model of acute cerebral ischemia and provide the possibility of drug administration in the acute stage of cerebral ischemia, especially before entering the hospital.
Unlabelled: This study sought to investigate the anti-amyloid β (Aβ) and anti-neuroinflammatory effects of catalpol in an Alzheimer's disease (AD) mouse model. Methods: The effects of catalpol on Aβ formation were investigated by thioflavin T assay. The effect of catalpol on generating inflammatory cytokines from microglial cells and the cytotoxicity of microglial cells on HT22 hippocampal cells were assessed by real-time quantitative PCR, ELISA, redox reactions, and cell viability. APPswe/PS1ΔE9 mice were treated with catalpol, and their cognitive ability was investigated using the water maze and novel object recognition tests. Immunohistochemistry and immunofluorescence were used to probe for protein markers of microglia and astrocyte, Aβ deposits, and NF-κB pathway activity. Aβ peptides, neuroinflammation, and nitric oxide production were examined using ELISA and redox reactions. Results: Catalpol potently inhibited Aβ fibril and oligomer formation. In microglial cells stimulated by Aβ, catalpol alleviated the expression of the proinflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin (IL)-6, and inducible nitric oxide synthase (iNOS) but promoted the expression of the anti-inflammatory cytokine IL-10. Catalpol alleviated the cytotoxic effects of Aβ-exposed microglia on HT22 cells. Treatment with catalpol in APPswe/PS1ΔE9 mice downregulated neuroinflammation production, decreased Aβ deposits in the brains and alleviated cognitive impairment. Catalpol treatment decreased the number of IBA-positive microglia and GFAP-positive astrocytes and their activities of the NF-κB pathway in the hippocampus of APPswe/PS1ΔE9 mice. Conclusion: The administration of catalpol protected neurons by preventing neuroinflammation and Aβ deposits in an AD mouse model. Therefore, catalpol may be a promising strategy for treating AD.
Ischemia-induced angiogenesis is critical for blood flow restoration and tissue regeneration, but the underlying molecular mechanism is not fully understood. ATG7 (autophagy related 7) is essential for classical degradative macroautophagy/autophagy and cell cycle regulation. However, whether and how ATG7 influences endothelial cell (EC) function and regulates post-ischemic angiogenesis remain unknown. Here, we showed that in mice subjected to femoral artery ligation, EC-specific deletion of Atg7 significantly impaired angiogenesis, delayed the recovery of blood flow reperfusion, and displayed reduction in HIF1A (hypoxia inducible factor 1 subunit alpha) expression. In addition, in cultured human umbilical vein endothelial cells (HUVECs), overexpression of HIF1A prevented ATG7 deficiency-reduced tube formation. Mechanistically, we identified STAT1 (signal transducer and activator of transcription 1) as a transcription suppressor of HIF1A and demonstrated that ablation of Atg7 upregulated STAT1 in an autophagy independent pathway, increased STAT1 binding to HIF1A promoter, and suppressed HIF1A expression. Moreover, lack of ATG7 in the cytoplasm disrupted the association between ATG7 and the transcription factor ZNF148/ZFP148/ZBP-89 (zinc finger protein 148) that is required for STAT1 constitutive expression, increased the binding between ZNF148/ZFP148/ZBP-89 and KPNB1 (karyopherin subunit beta 1), which promoted ZNF148/ZFP148/ZBP-89 nuclear translocation, and increased STAT1 expression. Finally, inhibition of STAT1 by fludarabine prevented the inhibition of HIF1A expression, angiogenesis, and blood flow recovery in atg7 KO mice. Our work reveals that lack of ATG7 inhibits angiogenesis by suppression of HIF1A expression through upregulation of STAT1 independently of autophagy under ischemic conditions, and suggest new therapeutic strategies for cancer and cardiovascular diseases.
Objective To specify the effect of vagus nerve stimulation (VNS) on microglial polarization following ischemic-reperfusion and further investigate its underlying mechanism. Materials and methods Sprague-Dawley rats were randomly divided into the sham, ischemic reperfusion group (IR), IR+VNS groups. VNS intervention lasting for 1 hour was administered after 30 minutes of occlusion. We analyzed the expression of Arginase 1 (Arg1), the number of M2 microglial in the peri-infarction cortex and assessed the neurological scores at the 1, 3, 7 days after reperfusion to determine the research time point. Then, we assessed polarization status of microglial, the infarct volume, neurological scores, the cellular distribution of Toll-like Receptor 4 (TLR4), the TLR4-associated pathway protein and the p-NF-κB in microglial at 3 days after reperfusion. Results We found that VNS could increase the specific marker of M2 Arg1 and upregulate the M2 microglial after reperfusion, and the increase of Arg1, M2 microglial and the neurological scores was largest at the 3 days after reperfusion. VNS treatment significantly reduced the number and percent of M1, improved the number and percent of M2 and upregulated the M2 to M1 ratio without changing the number of total microglial at the 3 days after reperfusion. Moreover, VNS reduced the infarct volume and neurological deficits. In addition, VNS significantly reduced the microglial-specific TLR4, inhibited the activated TLR4/MyD88/NF-κB pathway following ischemic-reperfusion, and ultimately suppressed the p-NF-κB in microglial. Conclusion Our study revealed that VNS can promote the M1-to-M2 phenotype conversion to alleviate inflammatory response and brain injury through inhibition of TLR4/MyD88/NF-κB pathway in microglia following ischemic-reperfusion.
Full-text available
Vascular endothelial growth factor (VEGF) is a principal regulator of vasculogenesis and angiogenesis. VEGF expresses its effects by binding to two VEGF receptors, Flt-1 and KDR. However, properties of Flt-1 and KDR in the signal transduction of VEGF-mediated effects in endothelial cells (ECs) were not entirely clarified. We investigated this issue by using two newly developed blocking monoclonal antibodies (mAbs) against Flt-1 and KDR. VEGF elicits DNA synthesis and cell migration of human umbilical vein endothelial cells (HUVECs). The pattern of inhibition of these effects by two mAbs indicates that DNA synthesis is preferentially mediated by KDR. In contrast, the regulation of cell migration by VEGF appears to be more complicated. Flt-1 regulates cell migration through modulating actin reorganization, which is essential for cell motility. A distinct signal is generated by KDR, which influences cell migration by regulating cell adhesion via the assembly of vinculin in focal adhesion plaque and tyrosine-phosphorylation of focal adhesion kinase (FAK) and paxillin.
Full-text available
Context Tissue plasminogen activator is the only thrombolytic agent approved in the United States for treatment of acute ischemic stroke, and has limitations. Aptiganel hydrochloride is a novel and selective ligand for the ion-channel site of the N-methyl-D-aspartate receptor-channel complex and a promising neuroprotective agent in animal models of focal brain ischemia.Objective To determine whether aptiganel improves the clinical outcome for acute ischemic stroke patients.Design Nested phase 2/phase 3 randomized controlled trial conducted between July 1996 and September 1997.Setting One hundred fifty-six medical centers in the United States, Canada, Australia, South Africa, England, and Scotland.Participants A total of 628 patients with hemispheric ischemic stroke (50.3% male; mean age, 71.5 years).Interventions Patients were randomly assigned within 6 hours of stroke to receive 1 of 3 treatment regimens: high-dose aptiganel (5-mg bolus followed by 0.75 mg/h for 12 hours; n = 214); low-dose aptiganel (3-mg bolus followed by 0.5 mg/h for 12 hours; n = 200); or placebo (n = 214).Main Outcome Measures The primary efficacy end point was the Modified Rankin Scale score at 90 days after stroke onset. Secondary end points included mortality and change in National Institutes of Health (NIH) Stroke Scale score at 7 days after stroke.Results The trial was suspended by the sponsor and the independent data and safety monitoring board because of both a lack of efficacy and a potential imbalance in mortality. There was no improvement in outcome for either aptiganel (low-dose or high-dose) group compared with the placebo group at 90 days (median Modified Rankin Scale score for all 3 treatment groups = 3; P = .31). At 7 days, placebo-treated patients exhibited slightly greater neurological improvement on the NIH Stroke Scale than high-dose aptiganel patients (mean improvement for placebo group, −0.8 points vs for high-dose aptiganel, 0.9 points; P = .04). The mortality rate at 120 days in patients treated with high-dose aptiganel was higher than that in patients who received placebo (26.3% vs 19.2%; P = .06). Mortality in the low-dose aptiganel group was 22.5% (P = .39 vs placebo).Conclusions Aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful. The larger proportion of patients with favorable outcomes and lower mortality rate in the placebo group suggest that glutamate blockade with aptiganel may have detrimental effects in an undifferentiated population of stroke patients. Figures in this Article Ischemic stroke is the third leading cause of death in the United States. Epidemiological studies indicate that as many as 730 000 strokes occur annually in the United States,1 of which between 73% and 86% are ischemic.2 Up to half of all stroke survivors are disabled, a third of them seriously enough to require assistance in daily activities.3 However, to date, the thrombolytic agent tissue plasminogen activator is the only therapy approved in the United States and Canada for the treatment of acute ischemic stroke. The limitations of tissue plasminogen activator are well-known. It must be administered within 3 hours of symptom onset, it increases the risk of brain hemorrhage, and only patients in whom cerebral hemorrhage has been definitively excluded are eligible for treatment.4 The approval of tissue plasminogen activator for use in North America has provided impetus for a change in how stroke is perceived both by the general public and among health care professionals. Acute stroke is now widely viewed as a medical emergency. There is a theoretic window of opportunity for minimizing the disability associated with stroke by means other than acute thrombolysis. Injury caused by the initial brain ischemia is compounded by the release of excitatory neurotransmitters, such as glutamate, which precipitate the influx of sodium and calcium into neurons, contributing to secondary damage.5 These observations have led to the concept of improving the stroke outcome by inhibiting these secondary processes. Substances that block glutamate receptors have neuroprotective properties in animal stroke models.6- 8 However, none of the putative neuroprotective agents has yet proven efficacious in humans. Aptiganel hydrochloride (N-[1-naphtyl]-N-methyl-guanidine hydrochloride) is a selective ligand for the ion-channel site of the N-methyl-D-aspartate subtype of glutamate receptor. Aptiganel, when given up to 1 hour after permanent or temporary occlusion of the middle cerebral artery in rat models of ischemic stroke, reduced the amount of brain damage between 40% and 70%.9 Aptiganel produced a significant improvement in neurological outcome after hypothermic circulatory arrest,10 and decreased contusion volume and hemispheric swelling after traumatic brain jury in animal models.11 Aptiganel was efficacious in animal studies at a minimum plasma concentration of approximately 10 ng/mL under steady state and nonsteady-state conditions.12 The half life of aptiganel in humans is 4 hours, and the mean clearance is 18 mL/min per kilogram. It is 88%-protein bound and is metabolized by the liver with primary excretion via the feces. Safety studies indicate that aptiganel is relatively well tolerated in healthy human volunteers and acute stroke patients (who received study medication within 24 hours of stroke onset). Adverse effects include increases in heart rate and blood pressure and neurological disturbances, such as blurred vision, nystagmus, numbness, dizziness, and sedation with increasing doses.13 In preliminary studies, it was determined that the maximum tolerable dose in humans was a 5-mg bolus infused over 3 to 5 minutes followed by a 12-hour, constant-rate, maintenance infusion of 0.75 mg/h.12 The present study was designed to compare the efficacy and safety of 2 doses of aptiganel with placebo in patients with acute ischemic stroke. The 2 dosing regimens were designed to produce steady-state plasma concentrations of aptiganel of approximately 5 and 10 ng/mL.
Background: Therapeutic angiogenesis with vascular endothelial growth factor (VEGF) is a clinically promising strategy in ischemic disease. The pathophysiological consequences of enhanced vessel formation, however, are poorly understood. Methods: We here established mice overexpressing human VEGF165 under a neuron-specific NSE promoter, which exhibited an increased density of brain vessels under physiological conditions. We submitted these mice to transient focal ischemias, as induced by 90 and 30 minutes episodes of intraluminal middle cerebral artery (MCA) occlusions and examined the effects of brain-selective VEGF overexpression on ischemic injury, blood-brain barrier dysfunction, angiogenesis and regional cerebral blood flow (CBF). Results: Following 90 and 30 minutes episodes of MCA occlusions, VEGF overexpression significantly reduced neurological deficits, infarct volume, disseminate neuronal injury and caspase-3 activity. Brain swelling, on the other hand, was not influenced in VEGF-overexpressing animals, while sodium fluorescein extravasation was moderately increased, suggesting VEGF induces mild blood brain barrier leakage. In order to find out whether enhanced angiogenesis improves regional CBF in the ischemic brain, 14C-iodoantipyrine autoradiographies were performed. Autoradiographies revealed that VEGF overexpression reduces regional CBF in ischemic areas and increases blood flow values only outside the MCA territory, suggesting that enhanced angiogenesis facilitates hemodynamic steal phenomena. Conclusions: Our data suggest that brain-selective VEGF overexpression is neuroprotective via inhibition of executive cell death pathways, but worsens cerebral hemodynamics.
Aim: To investigate the effects of catalpol from Radix Rehmanniae on behavior outcome of rats with focal cerebral ischemia and the expression patterns of growth-associated protein-43 (GAP-43) in the cerebral cortex surrounding the ischemic core. Methods: 42 adult male Sprague-Dawley rats were randomized into 7 groups, including sham operation group, model group, normal saline control group, low dose, middle dose and high dose of catalpol treatment group (1, 5 and 10 mg·kg-1, ip, respectively) and citicoline treatment control group (0.4 mg·kg-1, ip). A small craniectomy was performed from the posterior zygoma and along the temporal ridge of the cranium extending ventrally to expose the right middle cerebral artery (MCA) and olfactory tract. The base of MCA was electrico-coagulated, and the permanent focal cerebral ischemia animal model was established. Animals were assigned to receive intraperitoneally either different does of catalpol treatment or citicoline treatment, once a day for 7 successive days, and the first dose was given at the time point of 6h post-operation. Attitudinal reflexes and muscle strength were assessed just before the first dose was given and 1, 4, 7 d and 15 d time points after operation. After 15 days of behavioral testing, animais were deeply anesthetized and then sacrificed. Brain tissue was removed as quickly as possible, and brain sections and brain tissue homogenate were prepared for studying the expression patterns of growth-associated protein-43 in the cerebral cortex surrounding the ischemic core using immunofluorescence histochemistry and Western blot. Results: Compared with the model group, in the normal saline control group and the citicoline control group, attitudinal reflexes and muscle strength in high dose and middle dose of catalpol treatment groups(10 and 5 mg·kg-1, respectively) were ameliorated significantly, and there was no obvious dysfunction in the sham group; the protein expression of GAP-43 in the model rats of the catalpol treatment group(1, 5 and 10 mg·kg-1) increased significantly, higher than those in any other experimental groups (P < 0.05). Conclusion: Catalpol can up-regulate the protein expression of GAP-43 in the cerebral cortex surrounding the ischemic core, and enhance axonal regeneration, Which would be an underlying substrate for catalpol improved the functional recovery of rats with focal cerebral ischemia.
We have examined the incidence and size of infarction after occlusion of different portions of the rat middle cerebral artery (MCA) in order to define the reliability and predictability of this model of brain ischemia. We developed a neurologic examination and have correlated changes in neurologic status with the size and location of areas of infarction. The MCA was surgically occluded at different sites in six groups of normal rats. After 24 hr, rats were evaluated for the extent of neurologic deficits and graded as having severe, moderate, or no deficit using a new examination developed for this model. After rats were sacrificed the incidence of infarction was determined at histologic examination. In a subset of rats, the size of the area of infarction was measured as a percent of the area of a standard coronal section. Focal (1-2 mm) occlusion of the MCA at its origin, at the olfactory tract, or lateral to the inferior cerebral vein produced infarction in 13%, 67%, and 0% of rats, respectively (N = 38) and produced variable neurologic deficits. However, more extensive (3 or 6 mm) occlusion of the MCA beginning proximal to the olfactory tract--thus isolating lenticulostriate end-arteries from the proximal and distal supply--produced infarctions of uniform size, location, and with severe neurologic deficit (Grade 2) in 100% of rats (N = 17). Neurologic deficit correlated significantly with the size of the infarcted area (Grade 2, N = 17, 28 +/- 5% infarction; Grade 1, N = 5, 19 +/- 5%; Grade 0, N = 3, 10 +/- 2%; p less than 0.05). We have characterized precise anatomical sites of the MCA that when surgically occluded reliably produce uniform cerebral infarction in rats, and have developed a neurologic grading system that can be used to evaluate the effects of cerebral ischemia rapidly and accurately. The model will be useful for experimental assessment of new therapies for irreversible cerebral ischemia.
Stroke most commonly results from occlusion of a major artery in the brain and typically leads to the death of all cells within the affected tissue. Mitochondria are centrally involved in the development of this tissue injury due to modifications of their major role in supplying ATP and to changes in their properties that can contribute to the development of apoptotic and necrotic cell death. In animal models of stroke, the limited availability of glucose and oxygen directly impairs oxidative metabolism in severely ischemic regions of the affected tissue and leads to rapid changes in ATP and other energy-related metabolites. In the less-severely ischemic “penumbral” tissue, more moderate alterations develop in these metabolites, associated with near normal glucose use but impaired oxidative metabolism. This tissue remains potentially salvageable for at least the first few hours following stroke onset. Early restoration of blood flow can result in substantial recovery of energy-related metabolites throughout the affected tissue. However, glucose oxidation is markedly decreased due both to lower energy requirements in the post-ischemic tissue and limitations on the mitochondrial oxidation of pyruvate. A secondary deterioration of mitochondrial function subsequently develops that may contribute to progression to cell loss. Mitochondrial release of multiple apoptogenic proteins has been identified in ischemic and post-ischemic brain, mostly in neurons. Pharmacological interventions and genetic modifications in rodent models strongly implicate caspase-dependent and caspase-independent apoptosis and the mitochondrial permeability transition as important contributors to tissue damage, particularly when induced by short periods of temporary focal ischemia.